Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Keryx drug candidate meets late-stage study goal
Yahoo/AP
Tuesday, November 30, 2010 - 9:16am
tags:
Keryx, ZerenaxT
Merck Names Kenneth Frazier CEO, Clark Stays as Chairman
Bloomberg
Tuesday, November 30, 2010 - 9:15am
tags:
Merck, Pharma CEOs, Kenneth Frazier
House Passes ‘Doc Fix’; Medicare Cuts Now Due to Kick in Jan. 1
WSJ Online
Tuesday, November 30, 2010 - 8:03am
tags:
Medicare, physicians, healthcare reform
Orexigen: Contrave FDA Panel Preview
TheStreet.com
Tuesday, November 30, 2010 - 8:02am
tags:
FDA, advisory panels, Orexigen, Contrave, obesity, Arena Pharmaceuticals, Vivus
Inhibitex: A Biotech Gem in the Enormous Hepatitis C Market
Seeking Alpha
Tuesday, November 30, 2010 - 7:59am
tags:
Inhibitex, hepatitis C, Pharmasset, Vertex Pharmaceuticals
Drug Maker Wrote Book Under 2 Doctors’ Names, Documents Say
NY Times, NY
Tuesday, November 30, 2010 - 7:56am
tags:
GSK, physician payments, Ghostwriting
Drugmaker Endo Diversifies Its Product Lineup Through Acquisitions
Investors.com
Monday, November 29, 2010 - 8:04pm
tags:
Endo, diversification
Here's How Teva Pharmaceutical May Be Failing You
Motley Fool
Monday, November 29, 2010 - 8:03pm
tags:
Teva Pharmaceuticals, Pfizer, Elan, Abbott Laboratories
5 Biotechs Investors Should Be Watching
Seeking Alpha
Monday, November 29, 2010 - 6:05pm
tags:
Amarin, Cyclacel, Neoprobe, Inhibitex, Repligen
Amarin Has All the Makings of an Attractive Acquisition Target
Seeking Alpha
Monday, November 29, 2010 - 4:00pm
tags:
Amarin, M&A
Neutral on Regeneron
Yahoo/Zacks.com
Monday, November 29, 2010 - 3:59pm
tags:
Regeneron, Novartis, Sanofi
Abbott Looks Like a Bargain
Yahoo/TheStreet.com
Monday, November 29, 2010 - 2:51pm
tags:
Abbott Laboratories
Drug groups face new generics threat
FT.com
Monday, November 29, 2010 - 2:50pm
tags:
generics, Roche, Merck, JNJ, Abbott Laboratories, GSK, AstraZeneca, Teva Pharmaceuticals, Hospira, Novartis
Tylenol Chief Keeps His Job Despite 11 Product Recalls
BNET Pharma
Monday, November 29, 2010 - 1:45pm
tags:
Tylenol, JNJ, recalls, McNeil
Spectrum expects FDA ruling on Fusilev by April 29
Yahoo/AP
Monday, November 29, 2010 - 1:42pm
tags:
FDA, Spectrum Pharmaceuticals, Fusilev, colon cancer
Pfizer, Incyte and Eli Lilly drug developments could transform future of rheumatoid arthritis therapy
FT.com
Monday, November 29, 2010 - 12:44pm
tags:
rheumatoid arthritis, Pfizer, Incyte, Eli Lilly, Rigel, JAK inhibitors, fostamatinib
Lessons From A Losing Biotech Portfolio
TheStreet.com
Monday, November 29, 2010 - 11:38am
tags:
biotech, Keryx, Ariad Pharmaceuticals, Allos, Vertex Pharmaceuticals, Seattle Genetics, Human Genome Sciences, Spectrum Pharmaceuticals, Geron, StemCells
Johnson & Johnson Units Sue Teva, Impax Over Generic Concerta
Bloomberg
Monday, November 29, 2010 - 11:35am
tags:
JNJ, Teva Pharmaceuticals, generics, lawsuits, Impax, Concerta, ADHD
Analysts: More pharma cuts, especially in marketing
Fierce Pharma
Monday, November 29, 2010 - 11:33am
tags:
layoffs, Pfizer, Sanofi, Bristol-Myers Squibb
Are Analysts Underestimating Sales for Avanir’s Nuedexta?
Seeking Alpha
Monday, November 29, 2010 - 11:32am
tags:
Avanir, Nuedexta, PBA

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.